##### Table of Contents



UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549
 FORM 10-KSB
 þ
    
    ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 For the Fiscal Year Ended December 31, 2006
 o
    
    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
 For the Transition Period From  to
 Commission File Number 000-52320
 SENTISEARCH, INC.
  Delaware
(State or other jurisdiction of 
incorporation or organization)
    
    20-5655648
(I.R.S. Employer
Identification Number)
 1482 East Valley RoadSanta Barbara, California
    
    93108
    
    (805) 684-1830(Address of principal executive office)
    
    (Postal Code)
    
    (Issuers telephone number)
 None
 Common Stock, $.0001 par value per
share
 o
 þ o
 o
 o þ




---



##### 



TABLE OF CONTENTS
 SENTISEARCH, INC.
FORM 10-KSB
 PART IITEM 1 DESCRIPTION OF BUSINESS
    
    
    1ITEM 2 DESCRIPTION OF PROPERTY
    
    
    4ITEM 3 LEGAL PROCEEDINGS
    
    
    4ITEM 4 SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
    
    
    4PART IIITEM 5 MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS
    
    
    5ITEM 6 MANAGEMENTS DISCUSSION AND ANALYSIS OR PLAN OF OPERATION
    
    
    5ITEM 7 FINANCIAL STATEMENTS
    
    
    F-1ITEM 8 CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
    
    
    10ITEM 8A. CONTROLS AND PROCEDURES
    
    
    10ITEM 8B. OTHER INFORMATION
    
    
    11PART IIIITEM 9 DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS AND CORPORATE GOVERNANCE; COMPLIANCE WITH SECTION 16(A) OF THE EXCHANGE ACT
    
    
    12ITEM 10 EXECUTIVE COMPENSATION
    
    
    13ITEM 11 SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
    
    
    14ITEM 12 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
    
    
    14ITEM 13 EXHIBITS
    
    
    16ITEM 14 PRINCIPAL ACCOUNTANT FEES AND SERVICES
    
    
    17EX-31: CERTIFICATIONEX-32: CERTIFICATION




---



##### Table of Contents



PART I
 Forward-looking Information
  
    
    discuss our future expectations;
    
    contain projections of our future results of operations or of our financial condition; and
    
    state other forward-looking information.
  
 ITEM 1 DESCRIPTION OF BUSINESS.
 Corporate History
  Overview
  1




---



##### Table of Contents



Licensed Products and Services
     2




---



##### Table of Contents




    
    food production;
    
    agricultural chemical companies;
    
    organic; and
    
    pharmaceutical companies.
   
    
    obtaining research and development grants;
    
    developing commercially feasible products;
    
    filing and obtaining additional patents;
    
    entering into licensing, marketing or joint venture agreements;
    
    applying the olfaction intellectual property to a commercially viable product;
    
    developing and implementing a marketing plan in conjunction with a partner or licensee;
    
    controlling quality and cost in the manufacturing process in conjunction with a partner
or licensee;
    
    selling products on a profitable basis in conjunction with a partner or licensee; and
    
    structuring an agreement that will enable us to enjoy the profits of our products.
 3




---



##### Table of Contents



Competition
  Employees
  Government Regulation
  
 ITEM 2 DESCRIPTION OF PROPERTY.
  
 ITEM 3 LEGAL PROCEEDINGS.
 Legal Proceedings
  
 ITEM 4 SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.
  4




---



##### Table of Contents



PART II
 
 ITEM 5 MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS.
 Market Information
  Bid PriceHigh
    
    Low2006 Fourth Quarter (commencing on October 1, 2006)
    
    
    0
    
    
    
    0
 Holders
  Dividends
  
 ITEM 6 MANAGEMENTS DISCUSSION AND ANALYSIS OR PLAN OF OPERATION.
 Forward-looking Information
 :
 
    
    discuss our future expectations;
    
    contain projections of our future results of operations or of our financial condition; and
    
    state other forward-looking information.
 
 5




---



##### Table of Contents



Introduction
   Critical Accounting Policies and Use of Estimates
  Impairment of intangibles
  Off-Balance-Sheet Arrangements
  6




---



##### Table of Contents



Plan of Operations
 General
     Plan of Operations over the Next 12 Months
   7




---



##### Table of Contents



Product Research and Development
  Acquisition of Plant and Equipment and Other Assets
  Number of Employees
  Operating Expenses
   Liquidity and Capital Resources
   8




---



##### Table of Contents



Inflation
  Recent Accounting Pronouncements
    9




---



##### Table of Contents



ITEM 7 FINANCIAL STATEMENTS.
 SENTISEARCH, INC.
(A Development Stage Company)
 INDEX TO FINANCIAL STATEMENTS
 Page No.Report of Independent Registered Accounting Firm
    
    
    F-2Financial Statements:Balance Sheet
    
    
    F-3Statements of Operations
    
    
    F-4Statements of Changes in Stockholders Equity (Deficiency)
    
    
    F-5Statements of Cash Flows
    
    
    F-6Notes to Financial Statements
    
    
    F-7
 F-1




---



##### Table of Contents



REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
 
     RAICH ENDE MALTER CO. LLP
 F-2




---



##### Table of Contents



SENTISEARCH, INC.
 (A Development Stage Company)
 
 Balance Sheet
 December 31, 2006
 ASSETSCurrent AssetsCash and cash equivalents
    
    $
    67,893Other AssetsLicense cost
    
    
    440,625Less:Accumulated amortization
    
    
    (331,533
    )109,092$
    176,985LIABILITIES AND STOCKHOLDERS EQUITYCurrent LiabilitiesAccounts payable and accrued expenses
    
    $
    39,210Stockholders EquityCommon stock  $0.0001 par value, 8,000,000 shares authorized,
7,694,542 shares issued and outstanding
    
    
    769Additional paid in capital
    
    
    998,565Deficit accumulated during development stage
    
    
    (861,559
    )137,775$
    176,985
  F-3




---



##### Table of Contents



SENTISEARCH, INC.  (A Development Stage Company)
 
 Statements of Operations
 For the PeriodApril 10, 2000For the
    
    
    (CommencementYears Ended
    
    
    of Business)December 31,
    
    
    Through2005
    
    
    2006
    
    
    December 31, 2006Revenues
    
    $
    
    
    
    $
    
    
    
    $
    Direct Costs
    
    
    

    
    
    
    

    
    
    
    Income After Direct Costs
    
    
        

    
    
    
    

    
    
    
        Operating ExpensesGeneral and administrative
    
    
    34,951
    
    
    
    255,065
    
    
    
    530,026Amortization
    
    
    25,919
    
    
    
    182,504
    
    
    
    331,533Net Loss
    
    $
    (60,870
    )
    
    $
    (437,569
    )
    
    $
    (861,559
    )Basic and Diluted Loss Per Share
    
    $
    (0.01
    )
    
    $
    (0.06
    )Weighted Average Shares Outstanding
    
    
    7,694,542
    
    
    
    7,694,542
  F-4




---



##### Table of Contents



SENTISEARCH, INC.  (A Development Stage Company)
 
 Statements of Changes in Stockholders Equity (Deficiency)
 Deficit AccumulatedSubscription
    
    
    Additional Paid-In
    
    
    During DevelopmentShares
    
    
    Amount
    
    
    Receivable
    
    
    Capital
    
    

Stage
    
    
    TotalBalance- April 10, 2000 -
commencement
of business
    
    
    
    
    
    $
    
    
    
    $
    
    
    
    $
    
    
    
    $
    
    
    
    $
    Net loss
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    (47,763
    )
    
    
    (47,763
    )Balance- December 31, 2000
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    (47,763
    )
    
    
    (47,763
    )Net loss
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    (63,169
    )
    
    
    (63,169
    )Balance- December 31, 2001
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    (110,932
    )
    
    
    (110,932
    )Net loss
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    (65,936
    )
    
    
    (65,936
    )Balance- December 31, 2002
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    (176,868
    )
    
    
    (176,868
    )Net loss
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    (77,083
    )
    
    
    (77,083
    )Balance- December 31, 2003
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    (253,951
    )
    
    
    (253,951
    )Net loss
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    (109,169
    )
    
    
    (109,169
    )Balance- December 31, 2004
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    (363,120
    )
    
    
    (363,120
    )Net loss
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    (60,870
    )
    
    
    (60,870
    )Balance- December 31, 2005
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    (423,990
    )
    
    
    (423,990
    )Net loss
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    (320,747
    )
    
    
    (320,747
    )Balance- October 2, 2006
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    (744,737
    )
    
    
    (744,737
    )Issuance of common stock -
October 3, 2006
    
    
    7,694,542
    
    
    
    769
    
    
    
    (769
    )
    
    
    
    
    
    
    
    
    
    
    Additional contribution of capital -
October 10, 2006
    
    
    
    
    
    
    
    
    
    
    769
    
    
    
    249,231
    
    
    
    
    
    
    
    250,000Contribution to capital of license
costs and assumption of liability -
October 10, 2006
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    749,334
    
    
    
    
    
    
    
    749,334Net loss
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    (116,822
    )
    
    
    (116,822
    )Balance- December 31, 2006
    
    
    7,694,542
    
    
    $
    769
    
    
    $
    
    
    
    $
    998,565
    
    
    $
    (861,559
    )
    
    $
    137,775
  F-5




---



##### Table of Contents



SENTISEARCH, INC.  (A Development Stage Company)
 
 Statements of Cash Flows
 For the PeriodApril 10, 2000For the
    
    
    (CommencementYears Ended
    
    
    of Business)December 31,
    
    
    Through2005
    
    
    2006
    
    
    December 31, 2006Cash Flows from Operating ActivitiesNet loss
    
    $
    (60,870
    )
    
    $
    (437,569
    )
    
    $
    (861,559
    )Adjustments to reconcile net loss to
net cash provided by operating
activities:Amortization
    
    
    (25,919
    )
    
    
    182,504
    
    
    
    331,533Increase in accounts payable
and accrued expenses
    
    
    34,951
    
    
    
    72,958
    
    
    
    347,919
    
    
    
    (182,107
    )
    
    
    (182,107
    )Cash Flows from Financing ActivitiesProceeds from issuance of stock
    
    
    
    
    
    
    250,000
    
    
    
    250,000Net Increase in Cash and Cash Equivalents
    
    
    
    
    
    
    67,893
    
    
    
    67,893Cash and Cash Equivalents- beginning
    
    
    
    
    
    
    
    
    
    
    Cash and Cash Equivalents- end
    
    $
    
    
    
    $
    67,893
    
    
    $
    67,893Supplemental Disclosures of Cash Flow
InformationNoncash from financing activities:Assumption of liability by
Sentigen Holding Corp.
    
    $
    
    
    
    
    308,709
    
    
    $
    308,709Stock of Sentigen Holding Corp.
issued for license costs
    
    $
    
    
    
    $
    
    
    
    $
    440,625
  F-6




---



##### Table of Contents



Notes to Financial Statements
 1. Organization and Nature of Operations
    2. Basis of Presentation
    F-7




---



##### Table of Contents



3. Summary of Significant Accounting Policies
 a.
    
    Cash and Cash Equivalents Cash and cash equivalents include liquid investments
with maturities of three months or less at the time of purchase.b.
    
    License Costs The costs of intangible assets that are purchased from others
for use in research and development activities and that have alternative future uses
(in research and development projects or otherwise) are accounted for in accordance
with FASB Statement No. 142, Goodwill and Other Intangible Assets. The amortization
of those intangible assets used in research and development activities is a research
and development cost. However, the costs of intangibles that are purchased from others
for a particular research and development project and that have no alternative future
uses (in other research and development projects or otherwise) and therefore no
separate economic values are research and development costs at the time the costs are
incurred. We determined that the licensing costs arising from our exclusive licensing
agreement with The Trustees of Columbia University have alternative future uses. These
costs have been capitalized and are being amortized on a straight-line basis through
April 2010 (see Note 5).c.
    
    Impairment Intangible and long-lived assets are reviewed for impairment
whenever events or changes in circumstances indicate that the carrying amount of the
assets may not be fully recoverable. A review for impairment includes comparing the
carrying value of an asset to an estimate of the undiscounted net future cash inflows
over the life of the asset or fair market value. An asset is considered to be impaired
when the carrying value exceeds the calculation of the undiscounted net future cash
inflows or fair market value. An impairment loss is defined as the amount of the
excess of the carrying value over the fair market value of the asset. We believe that
none of our intangible and long-lived assets are impaired as of December 31, 2006 (see
Note 5).d.
    
    Estimates The preparation of financial statements in conformity with
generally accepted accounting principles requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the dates of the financial statements and the
reported amounts of revenues and expenses during the reporting periods. Actual results
could differ from those estimates.e.
    
    Income Taxes Certain income and expense items are accounted for differently
for financial reporting and income tax purposes. Deferred tax assets and liabilities
are determined based on the difference between the financial statement and income tax
basis of assets and liabilities and the tax effect of net operating loss and tax credit
carry-forwards applying the enacted statutory tax rates in effect
 F-8




---



##### Table of Contents



for the year in which the differences are expected to reverse. Valuation allowances
are established if it is determined to be more likely than not that deferred tax
assets will not be recovered.f.
    
    Loss Per Share The accompanying financial statements include loss per share
calculated as required by FASB Statement No. 128 Earnings Per Share on a pro-forma
basis as if we were a separate entity from the period April 10, 2000 (commencement of
business) until October 3, 2006 (our date of incorporation). Basic loss per share is
calculated by dividing net loss by the weighted average number of shares of common
stock outstanding. Diluted loss per share include the effects of securities
convertible into common stock, consisting of stock options, to the extent such
conversion would be dilutive. FASB Statement No. 128 prohibits adjusting the
denominator of diluted Earnings Per Share for additional potential common shares when a
net loss from continuing operations is reported. As of December 31, 2006, SentiSearch,
Inc. had no such securities outstanding or exercisable.g.
    
    Fair Value of Financial Instruments The carrying value of cash and cash
equivalents and accounts payable and accrued expenses payable approximates fair value
because of the short-term maturity of those instruments.
 4. Income Taxes
   December 31,
    
    
    December 31,2005
    
    
    2006Net operating loss carryforwards
    
    $
    169,596
    
    
    $
    2,887Amortization
    
    
    
    
    
    
    43,842Less: Valuation allowance
    
    
    (169,596
    )
    
    
    (46,729
    )Net deferred tax assets
    
    $
    
    
    
    $
    
  F-9




---



##### Table of Contents



For the period April 10, 2000(Commencement ofFor the year ended
    
    
    For the year ended
    
    
    Predecessor Business) toDecember 31, 2005
    
    
    December 31, 2006
    
    
    December 31, 2006At Statutory Rates
    
    $
    (20,696
    )
    
    $
    (148,774
    )
    
    $
    (292,930
    )State income taxes, net
of federal benefit
    
    
    (3,652
    )
    
    
    (26,254
    )
    
    
    (51,694
    )NOLs utilized by Sentigen
    
    
    
    
    
    
    297,895
    
    
    
    297,895Increase in valuation allowance
    
    
    24,348
    
    
    
    (122,867
    )
    
    
    46,729Provision for income taxes
    
    $
    
    
    
    $
    
    
    
    $
    
  5. Exclusive License Agreement
     F-10




---



##### Table of Contents



For the years ended:
    
    
    
    
    
    Expected amortization expense2007
    
    
    
    
    
    $
    32,7272008
    
    
    
    
    
    
    32,7272009
    
    
    
    
    
    
    32,7272010
    
    
    
    
    
    
    10,911Total
    
    
    
    
    
    $
    109,092
 6. Recently Issued Accounting Pronouncements
    F-11




---



##### Table of Contents



F-12




---



##### Table of Contents



ITEM 8
    
    CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL
DISCLOSURE.
      
 ITEM 8A. CONTROLS AND PROCEDURES
 Controls and Procedures
  Changes in Internal Controls Over Financial Reporting
  10




---



##### Table of Contents



ITEM 8B. OTHER INFORMATION
  11




---



##### Table of Contents



PART III
 
 ITEM 9
    
    DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS AND CORPORATE GOVERNANCE;
COMPLIANCE WITH SECTION 16(A) OF THE EXCHANGE ACT
 Directors and Executive Officer
  Name
    
    Age
    
    PositionJoseph K. Pagano
    
    
    62
    
    
    Chief Executive Officer, Secretary, Treasurer and Chairman of the Board of DirectorsFrederick R. Adler
    
    
    81
    
    
    DirectorThomas J. Livelli
    
    
    53
    
    
    Director
     12




---



##### Table of Contents



Section 16(a) Beneficial Reporting Compliance
   Code of Ethics
  Committees
  
 ITEM 10 EXECUTIVE COMPENSATION.
  13




---



##### Table of Contents



ITEM 11 SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.
  Amount of BeneficialOwnership
    
    Percentage ofName of Beneficial Owner
    
    of Common Stock
    
    Common StockJoseph K. Pagano
    
    
    1,376,450
    (1)
    
    
    17.89
    %1482 East Valley Road, Box 608
Santa Barbara, California 93108Frederick R. Adler
    
    
    653,573
    
    
    
    8.49
    %1520 S. Ocean Boulevard
Palm Beach, Florida 33480Thomas J. Livelli
    
    
    119,380
    
    
    
    1.55
    %7541 Fallen Oak Drive
Verona, Wisconsin 53593D. H. Blair Investment Banking Corp.
    
    
    1,134,859
    (2)
    
    
    14.75
    %44 Wall Street
New York, New York 10005Executive officer and all directors as a group (3 persons)
    
    
    2,149,403
    
    
    
    27.93
    %
 
 (1)
    
    Includes 25,000 shares of common stock held of record by the Joseph K.
Pagano, Jr. Trust established for Mr. Paganos son. Mr. Pagano
disclaims beneficial ownership of all shares other than those held in
his name.(2)
    
    J. Morton Davis is the sole stockholder of D.H. Blair Investment
Banking Corp. The amount reported includes 10,000 shares owned by Mr.
Davis wife of which Mr. Davis disclaims beneficial ownership. 
 ITEM 12 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.
 Certain Relationships and Related Transactions
  14




---



##### Table of Contents



Director Independence
  15




---



##### Table of Contents



ITEM 13 EXHIBITS.
 Exhibit
    
    Description3.1
    
    Certificate of Incorporation of SentiSearch, Inc.*3.2
    
    Bylaws of SentiSearch, Inc.*4.1
    
    Specimen Common Stock Certificate of SentiSearch, Inc.**10.1
    
    Exclusive License Agreement dated April 10, 2000 between Sentigen
Biosciences, Inc. (formerly known as Sentigen Corp.), and The
Trustees of Columbia University in the City of New York.*10.2
    
    Consent to the Assignment to SentiSearch, Inc. of the Exclusive
License Agreement dated April 10, 2000 between Sentigen
Biosciences, Inc. (formerly known as Sentigen Corp.), and The
Trustees of Columbia University in the City of New York: (1)
Letter dated September 25, 2006 by Sentigen Biosciences, Inc.
requesting consent to assignment of the Exclusive License
Agreement, and (2) Letter dated October 17, 2006 by Columbia
University granting consent to the assignment of the Exclusive
License Agreement.*10.3
    
    Separation and Distribution Agreement, dated as of October 10,
2006, between Sentigen Holding Corp. and SentiSearch, Inc.*10.4
    
    Contribution Agreement, dated as of October 10, 2006, between
Sentigen Holding Corp. and SentiSearch, Inc.*10.5
    
    Patent Assignment, dated October 10, 2006, by Sentigen Holding
Corp. to SentiSearch, Inc.*10.6
    
    Form of Indemnification Agreement.*31
    
    Certification of Chief Executive Officer pursuant to Rule 13a-14
and Rule 15d-14(a), promulgated under the Securities and Exchange
Act of 1934, as amended.32
    
    Certification pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
 
 *
    
    Incorporated by reference to SentiSearchs Registration Statement on Form 10-SB filed with the
SEC on November 15, 2006, as amended. File No. 000-52320.**
    
    Incorporated by reference to SentiSearchs Registration Statement on Amendment No. 1 filed with
the SEC on November 29, 2006, as amended. File No. 000-52320. 16




---



##### Table of Contents



ITEM 14 PRINCIPAL ACCOUNTANT FEES AND SERVICES.
  December 31, 2006(i)   Audit Fees
    
    $
    58,500(ii)  Audit Related
Fees
    
    $
    0(iii) Tax Fees
    
    $
    0(iv) All Other Fees
    
    $
    0Total Fees
    
    $
    58,500
 Audit Fees
  Audit Related Fees
  Tax Fees
  All Other Fees
   Policy on Pre-Approval of Audit and Permissible Non-Audit Services of Independent Auditors
  17




---



##### Table of Contents



Signatures
  Date:
April 2, 2007
    
    /s/ Joseph K. Pagano

Joseph K. PaganoChief Executive Officer 
Secretary and Treasurer
  Name
    
    Position
    
    Date/s/ Joseph K. Pagano

Joseph K. Pagano
    
    Chief Executive Officer,
Secretary and Treasurer,
Chairman of the Board,
Principal Executive Officer
and Principal Financial and
Accounting Officer
    
    April 2, 2007/s/ Thomas J. Livelli
    
    Director
    
    April 2, 2007Thomas J. Livelli
 
 18




---



##### Table of Contents



EXHIBIT INDEX
 Exhibit
    
    Description3.1
    
    Certificate of Incorporation of SentiSearch, Inc.*3.2
    
    Bylaws of SentiSearch, Inc.*4.1
    
    Specimen Common Stock Certificate of SentiSearch, Inc.**10.1
    
    Exclusive License Agreement dated April 10, 2000 between Sentigen
Biosciences, Inc. (formerly known as Sentigen Corp.), and The
Trustees of Columbia University in the City of New York.*10.2
    
    Consent to the Assignment to SentiSearch, Inc. of the Exclusive
License Agreement dated April 10, 2000 between Sentigen
Biosciences, Inc. (formerly known as Sentigen Corp.), and The
Trustees of Columbia University in the City of New York: (1)
Letter dated September 25, 2006 by Sentigen Biosciences, Inc.
requesting consent to assignment of the Exclusive License
Agreement, and (2) Letter dated October 17, 2006 by Columbia
University granting consent to the assignment of the Exclusive
License Agreement.*10.3
    
    Separation and Distribution Agreement, dated as of October 10,
2006, between Sentigen Holding Corp. and SentiSearch, Inc.*10.4
    
    Contribution Agreement, dated as of October 10, 2006, between
Sentigen Holding Corp. and SentiSearch, Inc.*10.5
    
    Patent Assignment, dated October 10, 2006, by Sentigen Holding
Corp. to SentiSearch, Inc.*10.6
    
    Form of Indemnification Agreement.*31
    
    Certification of Chief Executive Officer pursuant to Rule 13a-14
and Rule 15d-14(a), promulgated under the Securities and Exchange
Act of 1934, as amended.32
    
    Certification pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
 
 *
    
    Incorporated by reference to SentiSearchs Registration Statement on Form 10-SB filed with the
SEC on November 15, 2006, as amended. File No. 000-52320.**
    
    Incorporated by reference to SentiSearchs Registration Statement on Amendment No. 1 filed with
the SEC on November 29, 2006, as amended. File No. 000-52320.